Research overview based on the cited scientific literature.

• Goal: Support sexual desire and arousal through central melanocortin receptor activation[3].

• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Proper storage preserves peptide quality.
• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure[9].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days and avoid freeze–thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Bremelanotide is a synthetic analog of α-melanocyte-stimulating hormone that acts as a non-selective melanocortin receptor agonist, predominantly targeting MC3R and MC4R[3]. In the central nervous system, MC4R activation enhances dopamine release in key brain reward and arousal regions including the nucleus accumbens and medial preoptic area, which increases sexual motivation and desire[3]. Unlike PDE5 inhibitors, bremelanotide does not directly affect the nitric oxide pathway; in men, its erectogenic effect is secondary to this central mechanism stimulating nitric oxide production in penile tissue[3]. Peripheral MC1R agonism accounts for side effects such as transient blood pressure elevation and skin hyperpigmentation (tanning)[3][5].

Observations from clinical trials and peer-reviewed literature.
• Clinical trials in premenopausal women with HSDD demonstrated significant improvements in sexual desire scores (FSFI-Desire) and reduced distress (FSDS-DAO) versus placebo[3].
• Early studies also suggest potential benefit in men, with intranasal PT-141 improving erectile responses and increasing arousal measures in women[1].
• Adverse effects are usually mild and transient: most commonly nausea (~40%), flushing, headache, and injection-site reactions[3][5].
• Transient increases in blood pressure have been reported; bremelanotide is not recommended for individuals with uncontrolled hypertension or cardiovascular disease[5][10].
• Skin darkening (hyperpigmentation) may occur with repeated use due to peripheral MC1R activation and is generally reversible[3].

Bremelanotide was studied by both intranasal and subcutaneous routes during clinical development. The following summarizes route-related findings reported in the cited literature and does not constitute a protocol or recommendation.

• Early intranasal research: PT-141/bremelanotide was evaluated intranasally in healthy men and men with erectile dysfunction, with pharmacokinetic and pharmacodynamic effects reported in controlled clinical studies[12].

• Female intranasal research: A randomized, double-blind study evaluated a single intranasal exposure in premenopausal women with female sexual arousal disorder and reported effects on subjective measures of desire and arousal[13].

• Route-development limitation: Intranasal bremelanotide showed substantial variability in bioavailability, creating less predictable exposure. This contributed to development of the subcutaneous formulation[11].

• Blood-pressure considerations: The intranasal development program raised concerns regarding variable exposure and transient blood-pressure effects, which contributed to further evaluation of the subcutaneous route[11].

• Current approved formulation: Bremelanotide was subsequently developed and approved in the United States as a subcutaneous formulation for acquired, generalized hypoactive sexual desire disorder in premenopausal women[10][15].

• Adverse effects in early intranasal studies included nausea and flushing, while later subcutaneous clinical trials also commonly reported nausea, flushing, and headache[12][15].

• Evidence limitation: Findings from earlier intranasal studies and later subcutaneous trials involve different study populations, formulations, and development stages and should not be treated as interchangeable dosing or administration guidance.